Centrum Neurologii Krzysztof Selmaj

Łódź 10 trials 4 recruiting

10 Registered trials

4 Currently recruiting

Organisation

Centrum Neurologii Krzysztof Selmaj

Location

Łódź, Poland

Identifier

ORL-000003119

Address

ul. Tylna 12, 90-324, Poland

Departments

n/a
NA
NA/ND

Clinical trials at this site (10)

Search interface

Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis Recruiting

2025-523726-40-00 Multiple Sclerosis 5 2026-06-24
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Site… Recruiting

2025-523757-33-00 multiple sclerosis 4 2026-05-07
Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting

2024-519284-18-00 Relapsing multiple sclerosis 5 2025-06-18
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with chronic inflammatory demyel… Recruiting

2023-507885-21-00 Chronic Inflammatory Demyelinating Polyneuropathy 4 2020-08-18
A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Ended

2024-517980-22-00 Multiple Sclerosis (MS) 4 2025-12-10
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants… Ended

2024-512319-40-00 Subjects with relapsing multiple sclerosis (relapsing r 5 2025-07-01
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended

2022-502609-14-00 Relapsing multiple sclerosis (RMS) 5 2020-12-09
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended

2022-502618-95-00 Relapsing multiple sclerosis (RMS) 5 2020-11-24
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended

2023-505980-36-00 Primary progressive multiple sclerosis (PPMS) 5 2019-09-19